1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6A4723FB475C9F8E46525830C0035E0AD
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/rare-diseases-what-it-takes-to-build-strong-field-based-medical-teams
18
19
203.94.129.211
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




Products & Services Medical Affairs Medical Science Liaison

Rare Diseases: What It Takes To Build Strong Field-based Medical Teams

ID: POP-300


Features:

2 Info Graphics

28 Data Graphics

310+ Metrics


Pages: 37


Published: 2018


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
Building strong field-based medical teams is critical for developing a well-informed advocacy base for a company's rare disease franchise. But with high expectations - both internal and external - regarding the types of activities and services provided by field-based medical teams, it is important to clearly assign distinct roles and responsibilities to each liaison type and implement strong outreach strategies.

Best Practices, LLC undertook this research to identify the most effective tactics and strategies used by pharmaceutical and biotechnology companies to deploy successful field-based medical teams in support of rare disease franchises. This report delivers benchmarks around staffing, reporting levels, time allocation for key activities, outreach strategy, engagement frequency, proactive vs. reactive interactions, communication channels, performance effectiveness, and innovative use of technology.

Industries Profiled:
Biotech; Pharmaceutical; Biopharmaceutical; Health Care


Companies Profiled:
BioMarin; Ipsen; Intercept; Novartis; Novelion Therapeutics; Novo Nordisk; Pfizer; Prometic; Sanofi Genzyme; Shire; Ultragenyx; Vifor Pharma

Study Snapshot

Best Practices, LLC engaged 15 leaders from 12 companies in this research through a benchmarking survey. Report insights are presented into three segments: Total Benchmark Class (15 respondents), US Only Class (8 respondents) and Excluding-US Class (5 respondents).

Key topics covered in this report include:

  • Staffing and Reporting
  • Business Operations
  • Outreach Strategy
  • Performance Measurements and Improvements


Key Findings

Sample key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Leaders of field medical teams tend to report to VP level. MSLs are most typical roles within field teams.
  • MSLs are typically the primary contacts who engage with HCPs and KOLs. About 50 and 40 interactions are made by field teams / year with HCPs and KOLs respectively.
  • KOL management and scientific interactions are two activities conducted most frequently.

Table of Contents

I.
Executive Summarypg. 3
Methodology, Segmentation
Key Findings and Recommendations
II.
Participant Profilepg. 5
Geographic and Therapeutic Focus
III.
Staffing & Reportingpg. 7
Reporting Levels
Field-Based Medical Team Member Types
FTE Involvement
IV.
Business Operationspg. 14
Internal and Field Responsibilities
Number of Products Supported
V.
Outreach Strategypg. 20
Principal Contacts
Outreach Frequency
Types of Engagements
Interaction Examples and Insights Generated
VI.
Performance Measurement & Improvementspg. 31
Time Allocation
Qualitative Performance Metrics
Quantitative Performance Metrics

List of Charts & Exhibits

I. Staffing and Reporting
  • Job level of the person to whom the medical leader (direct medical manager) of rare disease field-based medical team function directly reports - Total Benchmark Class
  • Job level of the person to whom the medical leader (direct medical manager) of rare disease field-based medical team function directly reports - US Only Class and Excluding-US Class
  • Functions / roles that are a part of benchmarked organizations’ rare diseases field-based medical teams - Total Benchmark Class
  • Functions / roles that are a part of benchmarked organizations’ rare diseases field-based medical teams - US Only Class and Excluding-US Class
  • Total number of FTEs in each of the roles within rare disease field-based medical teams - Total Benchmark Class
  • Total number of FTEs in each of the roles within rare disease field-based medical teams - US Only Class and Excluding-US Class

II. Business Operations
  • Percentage of time allocated to internal and field responsibilities with HCPs and KOLs - Total Benchmark Class
  • Percentage of time allocated to internal and field responsibilities with HCPs - US Only Class and Excluding-US Class
  • Percentage of time allocated to internal and field responsibilities with KOLs - US Only Class and Excluding-US Class
  • Average number of pipeline and marketed products supported with HCPs and KOLs - Total Benchmark Class
  • Average number of pipeline and marketed products supported with HCPs and KOLs - US Only Class and Excluding-US Class

III. Outreach Strategy
  • Function / role serving as the principal contact for HCPs & KOLs - Total Benchmark Class
  • Function / role serving as the principal contact for HCPs - US Only Class and Excluding-US Class
  • Function / role serving as the principal contact for KOLs - US Only Class and Excluding-US Class
  • Number of Healthcare Professionals (HCPs) and Key Opinion Leaders (KOLs) with whom rare disease field-based medical teams interact or engage with during an average year - Total Benchmark Class
  • Number of Healthcare Professionals (HCPs) and Key Opinion Leaders (KOLs) with whom rare disease field-based medical teams interact or engage with during an average year - US Only Class and Excluding-US Class
  • Percentage of HCP interactions resulting in clinical insights for the company; examples of clinical insights
  • Percentage of KOL interactions resulting in clinical insights for the company; examples of clinical insights
  • Percentage of proactive and reactive HCP interactions
  • Percentage of proactive and reactive KOL interactions
  • HCP and KOL communication channels

IV. Performance Metrics and Performance Improvements
  • Number of ride-alongs conducted by an MSL Manager for HCPs and for KOLs
  • Occurrence of rare disease field-based medical team’s involvement in listed activities
  • Effectiveness of listed qualitative metrics in measuring the success of U.S.-based rare disease field-based medical teams
  • Effectiveness of listed quantitative metrics in measuring the success of U.S.-based rare disease field-based medical teams
  • Digital technologies being incorporated into field-based medical teams